BioNTech SE (NASDAQ: BNTX) reported Q4 EPS of EUR9.26, EUR1.14 better than the analyst estimate of EUR8.12. Revenue for the quarter came in at EUR4.28 billion versus the consensus estimate of EUR3.78 billion.

GUIDANCE:

Estimated BioNTech COVID-19 vaccine revenues for the 2023 financial year is ~ EUR5 billion

For earnings history and earnings-related data on BioNTech SE (BNTX) click here.